I was just reading about the success of Xtandi in the Phase III ARCHES trial when given along with ADT for extending radiographic PFS in mHSPCa. I’m trying to remember how this compares to Zytiga but am suffering from information overload at the moment. Does anyone know?
Randall
Written by
6357axbz
To view profiles and participate in discussions please or .
ARCHES only looked at radiographic progression-free survival so far. (Later, it will have survival results). The ENZAMET trial is being presented at the ASCO meeting today, I think. It has data on overall survival.
LATITUDE had a 33 month RPFS for Zytiga, but ARCHES has not reached the median RPFS for Xtandi. Median RPFS has been reached for the placebo group (19.45 months).
Both of these drugs can come with significant side effects. Xtandi with significant fatigue and Zytiga with major coronary concerns. These issues might give you an opportunity to argue for one drug over the other.
Besides the price favoring Zytiga, you have to take prednisolone with it. Also you are supposed to take it 2 hrs after or before a meal i think. Also, more blood test are required to keep check on yor liver funtion. Xtandi you dont.
Purely anecdotal here but I’ve been on Xtandi for about four and a half years now along with Lupron, Avodart and Metformin (Snuffy Myers protocol). PSA still undetectable and scans clear of active disease. Hoping for a long run.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.